$1.65
3.13% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US19188J3005
Symbol
COCP

Cocrystal Pharma Inc Stock price

$1.65
-0.11 6.25% 1M
-0.27 14.06% 6M
-0.37 18.32% YTD
-0.11 6.25% 1Y
-3.92 70.39% 3Y
-22.35 93.13% 5Y
-311.55 99.47% 10Y
+1.55 1,550.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.05 3.13%
ISIN
US19188J3005
Symbol
COCP
Industry

Key metrics

Basic
Market capitalization
$16.3m
Enterprise Value
$9.4m
Net debt
positive
Cash
$6.9m
Shares outstanding
10.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
70.8%
Return on Equity
-189.0%
ROCE
-184.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-16.0m | $-17.5m
EBIT
$-16.1m | $-14.2m
Net Income
$-15.9m | $-11.0m
Free Cash Flow
$-14.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
8.5% | 2.2%
EBIT
8.8% | 21.3%
Net Income
5.4% | 38.7%
Free Cash Flow
8.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.5
Short interest
0.0%
Employees
11
Rev per Employee
$0.0
Show more

Is Cocrystal Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Cocrystal Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Cocrystal Pharma Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Cocrystal Pharma Inc forecast:

Buy
88%
Hold
13%

Financial data from Cocrystal Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.11 5.11
15% 15%
-
- Research and Development Expense 11 11
23% 23%
-
-16 -16
8% 8%
-
- Depreciation and Amortization 0.11 0.11
39% 39%
-
EBIT (Operating Income) EBIT -16 -16
9% 9%
-
Net Profit -16 -16
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cocrystal Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cocrystal Pharma Inc Stock News

Neutral
GlobeNewsWire
7 days ago
All CDI-988 doses, ranging from 100 mg to 1200 mg, in the Phase 1 study were well tolerated Company expects to initiate Phase 1b study with CDI-988 in norovirus-infected healthy subjects later this year Lack of approved norovirus treatments or vaccines creates critical unmet medical need BOTHELL, Wash., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the presen...
Neutral
GlobeNewsWire
about one month ago
BOTHELL, Wash., July 10, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for an oral presentation at the 9th International Calicivirus Conference being held September 7-11, 2025 in Banff, Alberta, Canada.
Neutral
GlobeNewsWire
2 months ago
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health System Research Symposium (MHSRS) being held August 4-7 in Kissimmee, Fla.
More Cocrystal Pharma Inc News

Company Profile

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.

Head office United States
CEO Sam Lee
Employees 11
Founded 2008
Website www.cocrystalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today